drugset / Trial / NCT06911606
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
Phase 2
Recruiting
45 enrolled
Guangdong Provincial People's Hospital
Guangzhou No.12 People's Hospital · collabLiaoning Cancer Hospital & Institute · collabSecond Xiangya Hospital of Central South University · collab
NaSingle-groupOpen-labelTreatment
Summary
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC
Timeline
- Start
- 2024-05-22
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | — |